Side-by-side · Research reference

BPC-157vsThymalin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2Reviewed9/53 cited

BHuman-MechanisticDraft12/40 cited

BPC-157

Stable Gastric Pentadecapeptide · Healing

250–500 mcgDaily doseHwang 2016

Phase 2Evidence levelHwang 2016 Sikiric 2018

~30 minHalf-life (est.)

SQ or IM · Local · Once or twice daily

Thymalin

Immune restorer · Russian peptide bioregulator

5–10 mgPer cycle doseKhavinson 2002

HumanMechanisticKhavinson 2002

HoursHalf-life (est)

IM · Daily for 5–10 days · 1-2×/year

01Mechanism of Action

Parameter

BPC-157

Thymalin

Primary target

VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2014 Sikiric 2018

T-cell precursors + thymus-axis maturation pathwayKhavinson 2002

Pathway

Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2014

Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymusKhavinson 2002

Downstream effect

Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018

Restored T-cell populations, improved immune surveillance, reduced infection rates in elderlyKhavinson 2002

Feedback intact?

No known endogenous receptor; mechanism still under investigation

—

Origin

Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018

Polypeptide fraction isolated from calf thymus extractKhavinson 2002

Antibody development

—

02Dosage Protocols

Parameter

BPC-157

Thymalin

Standard dose

250–500 mcg / dayHwang 2016

Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.

5–10 mg / day IM × 5–10 daysKhavinson 2002

Frequency

Once or twice daily

Split dosing reported anecdotally for chronic injury.

Once daily during cycle

Lower / starter dose

200 mcg / day

Conservative starter for new users.

2.5 mg / day

Evidence basis

Animal-strong + Phase 2 clinicalSikiric 2018 Hwang 2016

Russian clinical + in vitroKhavinson 2002

Duration

2–4 weeks (acute injury); 4–8 weeks (chronic)

Anecdotal; no long-term human safety data.

5–10 day cycles, 1–2× per year

Reconstitution

Bacteriostatic water, 1–2 mL

Saline or bacteriostatic water

Timing

Local SQ to injury site preferred (anecdotal)

Systemic SQ also used; oral bioavailability shown in animal studies.

Morning preferred

Half-life

~30 min plasma (estimated)

Tissue half-life longer; mechanism may explain durable effect.

Hours (estimated)

04Side Effects & Safety

Parameter

BPC-157

Thymalin

Injection site reaction

Mild irritation (anecdotal)

Mild erythema at IM site

GI symptoms

None reported in PL-14736 Phase 2

—

Cardiovascular

Not reported

—

Cancer risk

Theoretical concern via VEGF angiogenesis pathwaySikiric 2018

—

Antibody formation

No data (no long-term human trials)

—

Pregnancy / OB

Avoid — insufficient safety data

Avoid

Long-term safety

Unknown beyond Phase 2 trial duration

Limited Western data

Drug interactions

None established

—

Allergic reaction

—

Rare hypersensitivity to bovine-derived polypeptide

Autoimmune flare

—

Theoretical risk in active autoimmune disease

Absolute Contraindications

BPC-157

·Pregnancy / breastfeeding
·Known active malignancy (theoretical VEGF concern)

Thymalin

·Pregnancy / breastfeeding
·Bovine protein hypersensitivity

Relative Contraindications

BPC-157

·History of cancer
·Concurrent VEGF inhibitor therapy (theoretical)
·Acute thrombotic events

Thymalin

·Active autoimmune disease
·Concurrent immunosuppressant therapy

05Administration Protocol

Parameter

BPC-157

Thymalin

1. Reconstitution

Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.

Add 1–2 mL saline or bacteriostatic water per 10 mg vial.

2. Injection site

Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.

Intramuscular — deltoid or gluteal. Rotate sites.

3. Timing

No strict timing requirement. Most users dose once or twice daily, often morning + evening.

Morning preferred during cycle.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.

Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.

5. Needle

27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.

23–25G, 25–38 mm IM needle.

06Stack Synergy

BPC-157

+ TB-500

Strong

View TB-500 →

BPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.

BPC-157: 250–500 mcg SQ · daily
TB-500: 2 mg SQ · 2× per week
Primary benefit: Tendon/ligament/muscle repair via complementary angiogenesis + migration

Thymalin

+ Thymosin α-1

Moderate

View Thymosin α-1 →

Thymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.

Thymalin: 5–10 mg IM · daily × 7 days
Thymosin α-1: 1.6 mg SQ · 2× weekly during the cycle
Primary benefit: Broad thymic restoration + targeted immune activation

Khavinson 2002 Camerini 2001